StockUS listing USCELCNASDAQHealthcareCapital Destroyer

Celcuity LLC(CELC) Stock Analysis | Healthcare

USD --+0.00%
Reward48Moderate
Risk41Moderate
75%Data
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.61Bn
Reward Ratingⓘ48 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ41 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CELC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Celcuity LLC?

, a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

AI Brief Pro

The brief on Celcuity LLC

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Celcuity LLC?

, a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.61B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (48)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.132
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
23,100,000 shares
$317.8M
0
6-9months
937,000 shares
$5.1M
0
9-12months
424,100 shares
$2.8M
0